Arbutus Biopharma Corp

A clinical-stage virology company developing a functional cure for chronic hepatitis B (HBV).

ABUS | NDAQ

Overview

Corporate Details

ISIN(s):: CA03879J1003 (+2 more)
LEI:
Country:: United States of America
Address:: 701 VETERANS CIRCLE, 18974 WARMINSTER
Website:: https://www.arbutusbio.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Arbutus Biopharma Corp. is a clinical-stage biopharmaceutical company focused on virology, with a primary mission to develop a functional cure for chronic hepatitis B virus (HBV) infection. The company's strategy centers on developing combination drug regimens that attack the virus through multiple, complementary mechanisms. This multi-pronged approach aims to suppress viral DNA replication, reduce viral antigens (specifically HBsAg), and boost the host's immune response. Its innovative virology portfolio is led by imdusiran, an RNAi therapeutic being investigated as a cornerstone therapy in its HBV clinical studies. Arbutus leverages a team with deep scientific and commercial expertise to advance its pipeline for conditions with significant unmet medical needs.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Arbutus Biopharma Corp filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Arbutus Biopharma Corp

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Arbutus Biopharma Corp via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
BRIGHT MINDS BIOSCIENCES INC. Developing next-gen serotonergic drugs for neurological and psychiatric disorders like epilepsy.	United States of America	DRUG
BRISTOL MYERS SQUIBB CO Develops innovative medicines for oncology, immunology, and cardiovascular diseases.	United States of America	BMY
BUKWANG PHARMACEUTICAL IND CO.,LTD R&D pharma firm developing drugs for CNS disorders, oncology, and metabolic diseases.	South Korea	003000
Burning Rock Biotech Ltd Offers NGS-based diagnostics for precision oncology, from detection to clinical trial support.	United States of America	BNR
C4 Therapeutics, Inc. Developing protein degrader medicines to treat cancer and other serious diseases.	United States of America	CCCC
Cabaletta Bio, Inc. Develops engineered T cell therapies for a curative reset in autoimmune diseases.	United States of America	CABA
Cadrenal Therapeutics, Inc. Developing novel anticoagulant therapies for high-risk cardiovascular patients.	United States of America	CVKD
CalciMedica, Inc. Develops CRAC channel inhibitors for critical illnesses like acute pancreatitis & AKI.	United States of America	CALC
Calidi Biotherapeutics, Inc. Develops immunotherapies using stem cells to deliver oncolytic viruses against solid tumors.	United States of America	CLDI
Calliditas Therapeutics Develops and commercializes novel treatments for rare renal and hepatic diseases like IgA nephropathy.	Sweden	CALTX